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Introduction
Several lines of evidence suggest that cyclooxygenase-2 (COX-
2) is a rational target for anticancer therapy. Epidemiological
studies have shown that use of nonsteroidal anti-inflammatory
drugs (NSAIDs), prototypic inhibitors of COX, is associated with
a reduced risk of several malignancies (Thun et al., 2002). In a
recent observational study, selective inhibitors of COX-2 were
found to protect against the development of colorectal neopla-
sia (Rahme et al., 2003). Consistent with these findings, tumor
formation and growth were reduced in animals treated with
selective inhibitors of COX-2 or engineered to be COX-2-defi-
cient. Selective COX-2 inhibitors have been used extensively to
treat patients with arthritis and possess an excellent safety pro-
file. Based on this constellation of findings, numerous clinical tri-
als are under way to investigate the potential efficacy of
selective COX-2 inhibitors in the prevention and treatment of a
variety of cancers. Here we focus on the rationale for targeting
COX-2 as a strategy to prevent or treat human malignancies.
Prostaglandin biosynthesis
COX enzymes catalyze the synthesis of prostaglandins (PGs)
from arachidonic acid (Figure 1). The first step in PG synthesis
is hydrolysis of phospholipids to produce free arachidonic acid
in a reaction catalyzed by phospholipase A2. Next, COX cat-
alyzes a reaction in which molecular oxygen is inserted into
arachidonic acid to form an unstable intermediate, PGG2, which
is rapidly converted to PGH2. Specific isomerases then convert
PGH2 to PGs and thromboxane A2 (TxA2).
There are two isoforms of COX: COX-1 and COX-2. The two
forms differ in many respects (reviewed in Gupta and DuBois,
2001). COX-1 is expressed constitutively in most tissues and
appears to be responsible for the production of PGs that control
normal physiological functions, including maintenance of the gas-
tric mucosa, regulation of renal blood flow, and platelet aggrega-
tion. In contrast, COX-2 is undetectable in most normal tissues.
However, it is rapidly induced by both mitogenic and inflammato-
ry stimuli, resulting in enhanced synthesis of prostanoids in neo-
plastic and inflamed tissues. COX-2 can be selectively inhibited
even though the active sites of COX-1 and COX-2 have very sim-
ilar structures. A single substitution of isoleucine in COX-1 with
valine in the NSAID binding site of COX-2 creates a void volume
located to the side of the central active site channel in COX-2.
Compounds designed to bind in this additional space selectively
inhibit COX-2. In contrast to traditional NSAIDs that are dual
COX-1/COX-2 inhibitors, selective COX-2 inhibitors do not sup-
press platelet function or increase bleeding time. This difference
has significant practical implications. Selective COX-2 inhibitors
can be evaluated in combination with cytotoxic chemotherapy
without inhibiting platelet function and thereby increasing the risk
of a bleeding complication.
Regulation of COX-2 expression
Increased amounts of COX-2 are commonly detected in both
premalignant and malignant tissues (Table 1). Overexpression
of COX-2 is a consequence of deregulated transcriptional and
posttranscriptional control. Growth factors, cytokines, onco-
genes, and tumor promoters stimulate COX-2 transcription via
Ras and protein kinase C (PKC)-mediated signaling (Figure 2)
(Smith et al., 2000). For example, increased amounts of COX-2
have been observed in HER-2/neu-overexpressing breast can-
cers because of enhanced Ras signaling (Figure 2)
(Subbaramaiah et al., 2002). Depending on the stimulus and
cell type, different transcription factors, including AP-1, NF-IL6,
NF-κB, NFAT, and PEA3, can stimulate COX-2 transcription.
Although COX-2 transcription can be induced by many factors,
much less is known about negative effectors. Wild-type but not
mutant p53 can inhibit COX-2 transcription. Consistent with this
finding, increased COX-2 levels were detected in epithelial
malignancies that expressed mutant p53 (Ristimaki et al.,
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Figure 1. Arachidonic acid metabolism
Arachidonic acid, released from membrane phospholipids by phospholi-
pase A2 (PLA2), is metabolized by cyclooxygenases to prostaglandin H2
(PGH2) in two steps. PGH2 is converted to a variety of prostanoids by
specific isomerases.
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2002). Like p53, APC tumor suppressor gene status may also
be a determinant of COX-2 expression (Araki et al., 2003).
Taken together, these findings suggest that the balance
between activation of oncogenes and inactivation of tumor sup-
pressor genes modulates the level of expression of COX-2 in
tumors.
Posttranscriptional mechanisms also play a significant role
in regulating levels of COX-2 in tumors. The 3′-untranslated
region (UTR) of COX-2 mRNA contains a series of AU-rich ele-
ments (AREs) that control both mRNA decay and protein trans-
lation (Figure 2). Trans-acting ARE binding factors form stable
complexes with the COX-2 3′-UTR and regulate both COX-2
mRNA stability and translation. Enhanced binding of HuR, an
RNA binding protein, to the AU-enriched region of the COX-2 3′-
UTR contributes to the observed increase in message stability
in colon cancer (Dixon et al., 2001; Sengupta et al., 2003)
(Figure 2). Other proteins, e.g., tristetraprolin, AUF1, that bind to
the 3′-UTR can accelerate mRNA degradation (Sawaoka et al.,
2003). Deregulated translation may also contribute to overex-
pression of COX-2. Recently, TIA-1, an ARE binding protein,
was found to act as a translational silencer (Piecyk et al., 2000).
Deficient TIA-1 mRNA binding was observed in colon cancer
cells that overexpressed COX-2 protein (Dixon et al., 2003).
Collectively, these findings suggest that changes in the relative
abundance or binding activity of these functionally distinct ARE
binding proteins are likely to affect levels of COX-2 in tumors.
In any tumor type, the magnitude of COX-2 overexpression
is highly variable because of intrinsic biological differences.
However, much less attention has been given to the potential of
cancer therapy to modulate levels of COX-2. In fact, both radia-
tion treatment and chemotherapy can induce COX-2 and PG
biosynthesis (Choy and Milas, 2003;
Subbaramaiah et al., 2003) (Figure 2).
This has potential therapeutic implica-
tions that are discussed below (Altorki et
al., 2003).
Prostaglandin receptors, signaling,
and carcinogenesis
Overexpression of COX-2 leads to
increased levels of prostanoids in
tumors. Prostanoids affect multiple
mechanisms that have been implicated
in carcinogenesis. For example, PGE2
can stimulate cell proliferation and motility while inhibiting apop-
tosis and immune surveillance. Importantly, PGE2 can also
induce angiogenesis, at least in part, by enhancing the produc-
tion of proangiogenic factors including vascular endothelial
growth factor (VEGF). These important COX-2-dependent
mechanisms have been reviewed recently (Gupta and DuBois,
2001; Dannenberg et al., 2001; Gasparini et al., 2003). Defining
the signaling mechanisms by which prostanoids stimulate car-
cinogenesis is an active area of investigation.
Prostanoids (PGE2, PGF2α, PGD2, TxA2, and PGI2) exert
their biological actions by binding to G protein-coupled receptors
that contain seven transmembrane domains. Multiple prostanoid
receptors have been cloned and defined pharmacologically,
including four subtypes of the EP (PGE) receptor (EP1, EP2, EP3,
EP4), the DP receptor (PGD receptor), the FP receptor (PGF
receptor), the IP receptor (PGI receptor), and the TP receptor
(Tx receptor). PGE2 is the most abundant prostanoid detected in
the majority of epithelial malignancies. Because it can stimulate
tumor growth, numerous studies have attempted to elucidate the
link between PGE2, EP receptors, and carcinogenesis.
EP receptors play a significant role in the development and
growth of tumors. The availability of EP receptor knockout mice
has facilitated studies of tumor growth, angiogenesis, and
immune function. PGE2 promotes the formation of colorectal
cancer through activation of EP receptors. In support of this
idea, the induction of aberrant crypt foci by azoxymethane, a
colon carcinogen, was suppressed in EP1−/− and EP4−/− receptor
mice (Mutoh et al., 2002). In Apc∆716 mice, a murine model of
familial adenomatous polyposis (FAP), homozygous deletion of
the gene encoding the EP2 receptor caused a significant reduc-
tion in the number and size of intestinal polyps through inhibi-
F O C U S
Figure 2. Regulation of COX-2 expression in
cancers
COX-2 is induced by a variety of stimuli, includ-
ing oncogenes, growth factors, tumor promot-
ers (phorbol esters, PMA), and chemotherapy
(taxanes). Stimulation of PKC or Ras signaling
enhances mitogen-activated protein kinase
(MAPK) activity that results, in turn, in increased
COX-2 transcription. A variety of transcription
factors including AP-1 and NF-κB mediate the
induction of COX-2. COX-2 can also be regulat-
ed by posttranscriptional mechanisms. The 3′-
untranslated region (3′-UTR) of COX-2 mRNA
contains a series of AU-enriched elements (ARE)
that regulate message stability. Augmented
binding of HuR, an RNA binding protein, to the
AREs of the COX-2 3′-UTR is responsible, in part,
for the observed increase in COX-2 message
stability in some tumors.
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tion of angiogenesis (Sonoshita et al., 2001). Inhibition of angio-
genesis was due at least in part to a reduction in levels of VEGF.
The importance of host stromal PGE2-EP3 signaling was high-
lighted in a recent xenograft study that found a marked reduc-
tion in tumor-associated angiogenesis in EP3−/− mice (Amano et
al., 2003). PGE2 also exhibits potent immunosuppressive
effects by modulating dendritic cell function and causing an
imbalance between type 1 and type 2 cytokines (Sharma et al.,
2003). An important role has been established for the EP2
receptor in PGE2-mediated inhibition of dendritic cell differentia-
tion and function and for diminished antitumor cellular immune
responses in vivo (Yang et al., 2003).
Complementary in vitro studies have provided important
insights into procarcinogenic signaling mechanisms that are
activated by PGE2. For example, stimulation of either EP2 or EP4
activates TCF-β-catenin-mediated transcription that leads, in
turn, to enhanced expression of a variety of genes, e.g., cyclin
D1 and c-myc, which have been implicated in carcinogenesis
(Fujino et al., 2002) (Figure 3). Crosstalk between EP receptors
and the epidermal growth factor receptor (EGFR) may also con-
tribute to increased cell growth (Pai et al., 2002). As shown in
Figure 3, PGE2 activates the cAMP/protein kinase A (PKA)
pathway, resulting in increased expression of amphiregulin, a
ligand of EGFR (Shao et al., 2003). Enhanced production of
amphiregulin stimulates mitogenesis. PGE2 can also transacti-
vate EGFR via an intracellular Src-mediated event independent
of the release of an extracellular ligand of EGFR (Figure 3)
(Buchanan et al., 2003).
PGE2 also has organ site-specific effects. Estrogen stimu-
lates the growth of hormone-dependent breast cancer.The final
step in estrogen biosynthesis is catalyzed by aromatase, the
product of the CYP19 gene. Binding of PGE2 to EP receptors
stimulates adenylyl cyclase activity and increases production of
cAMP, which induces expression of the gene encoding aro-
matase via CREB (reviewed in Subbaramaiah and
Dannenberg, 2003). Consequently, estrogen biosynthesis is
enhanced, which leads to increased proliferation of tumor cells.
In addition to PGE2, other prostanoids, including TxA2 and PGI2,
impact on carcinogenesis, but less is understood about the
downstream signaling mechanisms (Daniel et al., 1999;
reviewed in Gupta and DuBois, 2001).
Preclinical evidence that targeting COX-2 inhibits
carcinogenesis
As mentioned above, COX-2-derived prostanoids have multiple
procarcinogenic effects. It is reasonable to postulate, therefore,
that inhibiting COX-2 will suppress carcinogenesis. To investi-
gate this possibility, numerous studies have been conducted in
experimental animals. The most specific data supporting a
cause-and-effect connection between COX-2 and carcinogene-
sis come from genetic studies. Multiparous female transgenic
mice engineered to overexpress human COX-2 in mammary
glands developed focal mammary gland hyperplasia, dysplasia,
and transformation into metastatic tumors (Liu et al., 2001). In a
related study, transgenic mice that overexpressed COX-2 in
basal keratinocytes developed epidermal hyperplasia and dys-
plasia (Neufang et al., 2001). This implies a causal association
F O C U S
Figure 3. PGE2 activates cellular signal transduction pathways that have
been implicated in carcinogenesis
PGE2 activates cellular signaling in an EP receptor-dependent fashion.
PGE2-mediated activation of EP2 and EP4 receptors leads to enhanced
adenylate cyclase activity and cAMP production. cAMP stimulates expres-
sion of PKA-CREB-dependent genes including amphiregulin. Amphiregulin,
a ligand of EGFR, activates EGFR-Ras-MAPK signaling. Additionally, activa-
tion of EP2 or EP4 enhances TCF-β-catenin-mediated transcription of genes
including cyclin D1. Both the cAMP/PKA and phosphoinositide 3-kinase
(PI3-K) pathways have been implicated in the activation of TCF-β-catenin-
mediated transcription.
Table 1. COX-2 is overexpressed in a variety of premalignant and 
malignant conditions
Organ Premalignancy Malignancy
Head and neck Leukoplakia Squamous cell carcinoma
Esophagus Barretts Adenocarcinoma, squamous cell
esophagus carcinoma
Stomach Metaplasia Adenocarcinoma
Colon Adenoma Adenocarcinoma
Liver Chronic hepatitis Hepatocellular carcinoma
Biliary system Bile duct Cholangiocarcinoma, 
hyperplasia adenocarcinoma of gall bladder 
Pancreas Pancreatic Adenocarcinoma
intraepithelial 
neoplasia
Breast Ductal carcinoma Adenocarcinoma
in situ
Lung Atypical Adenocarcinoma, squamous cell 
adenomatous carcinoma
hyperplasia
Bladder Dysplasia Transitional cell carcinoma, 
squamous cell carcinoma
Gynecologic Cervical Squamous cell carcinoma or 
intraepithelial adenocarcinoma of cervix,
neoplasia endometrial carcinoma
Penis Penile Squamous cell carcinoma
intraepithelial 
neoplasia
Skin Actinic keratoses Squamous cell carcinoma
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between COX-2 expression and the development of premalig-
nant lesions of the skin. Consistent with the overexpression
data, a marked reduction in the development of both intestinal
tumors and skin papillomas was observed in COX-2−/− mice
(Chulada et al., 2000; reviewed in Subbaramaiah and
Dannenberg, 2003). In another study, tumor growth was attenu-
ated in COX-2−/− mice compared with wild-type mice (Williams et
al., 2000). Tumor growth inhibition was attributed to a reduction
in angiogenesis. The importance of arachidonic acid metabo-
lism in tumorigenesis is underscored by the finding that knock-
ing out the COX-1 gene also protected against the formation of
intestinal and skin tumors (Chulada et al., 2000).
In addition to genetic evidence, numerous pharmacological
studies suggest that COX-2 is a bona fide therapeutic target.
Treatment with selective inhibitors of COX-2 reduced the forma-
tion of tongue, esophageal, intestinal, breast, skin, lung, and
bladder tumors in experimental animals (reviewed in
Subbaramaiah and Dannenberg, 2003). Collectively, these find-
ings indicate that selective COX-2 inhibitors might be useful for
preventing cancer. Selective COX-2 inhibitors also reduced the
growth and metastases of a variety of experimental tumors.
However, tumor regression has rarely been seen. It seems
unrealistic, therefore, to expect that selective COX-2 inhibitors
will be useful as monotherapy in treating cancer. In all likelihood,
selective COX-2 inhibitors will need to be given in conjunction
with standard anticancer therapy. In fact, preclinical studies
have shown that the antitumor effects of radiation, chemothera-
py, biotherapy, and photodynamic therapy can be potentiated by
cotreatment with a selective COX-2 inhibitor (reviewed in
Subbaramaiah and Dannenberg, 2003; Gasparini et al., 2003).
Taken together, the results of both genetic and pharmacological
studies suggest that COX-2 warrants investigation as a molecu-
lar target for the prevention and treatment of human cancer.
Use of selective COX-2 inhibitors to prevent or treat
human cancers
Prevention
To be useful in humans, a chemopreventive agent must have an
acceptable risk:benefit ratio. An individual’s personal risk of
developing cancer will impact on whether he or she is willing to
undertake preventive measures and tolerate potential side
effects. For example, an individual with a germline defect in a
tumor suppressor gene, such as APC, that predisposes to can-
cer is much more likely to be willing to undergo preventive ther-
apy than a person at average risk for cancer. In this context, it is
noteworthy that selective COX-2 inhibitors cause less injury to
the upper gastrointestinal tract than traditional NSAIDs
(Bombardier et al., 2000). The first human trial to evaluate the
anticancer properties of a selective COX-2 inhibitor was carried
out in FAP patients. This patient population was selected
because of the strength of the preclinical data and prior evi-
dence that sulindac, a dual inhibitor of COX-1/COX-2, reduced
the number of colorectal polyps in FAP patients. Treatment with
celecoxib 400 mg bid for 6 months caused a 28% reduction in
the number of colorectal polyps (p = 0.003) (Steinbach et al.,
2000). Based on these results, the US FDA approved celecoxib
as adjunctive therapy for the management of polyps in FAP
patients. Recently, rofecoxib, another selective COX-2 inhibitor,
was also found to decrease the number and size of rectal polyps
in FAP patients (Higuchi et al., 2003). Combination therapy, a
common strategy in cancer treatment, might also be applicable
to chemoprevention. To build upon the initial clinical findings, a
study has been initiated that will evaluate whether treatment
with difluoromethylornithine, an ornithine decarboxylase
inhibitor, augments the antitumor effects of celecoxib in FAP
patients. Another study will determine whether celecoxib can
suppress or delay the phenotypic expression of colorectal neo-
plasia in FAP genotype-positive, phenotype-negative children.
Because of similarities in the biology of FAP and sporadic col-
orectal cancer, therapeutic strategies that are effective in FAP
might also be applicable in patients with colorectal adenomas.
Adenomas are the precursors of most colorectal cancers.
Hence, treatments that reduce the formation of premalignant
adenomas should protect against the development of colorectal
cancers. Several large clinical trials are ongoing to assess the
efficacy of selective COX-2 inhibitors in preventing sporadic col-
orectal adenomas. A separate placebo-controlled study will
compare the effects of celecoxib, selenomethionine, or the com-
bination on adenoma recurrence.
As detailed above, selective inhibitors of COX-2 protect
against the formation of multiple tumor types in experimental
animals. Ongoing phase II studies are building upon these pre-
clinical findings by evaluating the potential efficacy of a selec-
tive COX-2 inhibitor in a variety of target organs. At-risk cohorts
include patients with oral premalignant lesions, Barrett’s dyspla-
sia, bronchial metaplasia, basal cell nevi, and actinic keratoses.
Given the frequent need for surgical intervention in conditions
such as Barrett’s dysplasia and oral leukoplakia, developing a
pharmacological approach to cause either regression or stabi-
lization of disease would represent a significant clinical
advance. Another study will evaluate whether a selective COX-2
inhibitor can delay or prevent the recurrence of superficial blad-
der cancer.
Treatment
Given the strength of the preclinical findings, selective COX-2
inhibitors are being evaluated in conjunction with chemotherapy
and radiotherapy in patients with cancers of the lung, colon,
breast, esophagus, pancreas, liver, cervix, and brain (reviewed
in Gasparini et al., 2003). Although many studies are under way,
it is too soon to know whether selective COX-2 inhibitors will
have a role in cancer therapy. A brief description of representa-
tive studies is given below.
Recently, a study was completed in patients with non-small-
cell lung cancer (NSCLC) (Altorki et al., 2003). Taxanes induce
COX-2 and PG biosynthesis (Figure 2) (Subbaramaiah et al.,
2003). Because PGs stimulate tumor growth, the induction of
COX-2 might reduce the efficacy of taxanes as anticancer
agents. Theoretically, coadministration of a selective COX-2
inhibitor should overcome any decrease in efficacy related to
the induction of COX-2 by taxanes. To test this hypothesis, a
phase II neoadjuvant trial was conducted in which celecoxib
was used in combination with paclitaxel/carboplatin (Altorki et
al., 2003). Overall clinical response rate was somewhat higher
than predicted from historical data, suggesting that the addition
of a selective COX-2 inhibitor enhanced the response to preop-
erative paclitaxel/carboplatin. This study also showed that treat-
ment with celecoxib 400 mg bid was sufficient to abrogate
intratumor COX-2 activity. This finding was important because
determining the appropriate dose for any form of targeted ther-
apy is challenging. Importantly, a placebo-controlled trial has
been initiated that will further evaluate the potential benefits of
using celecoxib in combination with paclitaxel/carboplatin.
Other phase I/II trials are evaluating selective COX-2 inhibitors
in combination with a range of agents, including docetaxel and
F O C U S
CANCER CELL : DECEMBER 2003 435
gemcitabine/cisplatin, in patients with different stages of
NSCLC (Gasparini et al., 2003).
Numerous trials are evaluating selective COX-2 inhibitors in
the treatment of colorectal cancer. A phase II trial is being con-
ducted to evaluate celecoxib with irinotecan, fluorouracil, and
leucovorin in patients with measurable, incurable colorectal
cancer. Another phase I/II trial is evaluating rofecoxib in combi-
nation with weekly irinotecan and infusional fluorouracil as sec-
ond-line therapy in advanced colorectal cancer. Preliminary
results suggest that the combination is feasible, safe, and active
but the therapeutic activity still needs to be defined (Gasparini
et al., 2003). Another important question concerns the use of
selective COX-2 inhibitors to prevent the recurrence of colorec-
tal cancer following potentially curative surgery. This question
will be addressed in a study utilizing rofecoxib. Based on
promising results in a retrospective study (reviewed in
Subbaramaiah and Dannenberg, 2003), a phase II study of
capecitabine and celecoxib will be carried out in patients with
metastatic colorectal cancer.
Clinical trials are under way to evaluate the use of selective
COX-2 inhibitors in the treatment of breast cancer. Encouraging
preliminary results have been reported in the neoadjuvant set-
ting (Chow et al., 2003). A pilot study of 32 patients compared
celecoxib and fluorouracil, epirubicin, and cyclophosphamide
(FEC) versus FEC alone for the treatment of locally advanced
breast cancer (reviewed in Gasparini et al., 2003). The combi-
nation arm appeared to be superior to FEC alone in terms of
clinical and pathological response rates. Other studies are
exploring the potential utility and toxicity of selective COX-2
inhibitors in combination with conventional chemotherapy
(mainly anthracyclines and taxanes).
In preclinical studies, selective COX-2 inhibitors enhanced
the sensitivity of tumors to radiation (reviewed in Choy and
Milas, 2003). Whether similar effects will be observed in
humans is being investigated. The Radiation Therapy Oncology
Group is conducting a phase I/II trial of celecoxib with limited
field radiation in patients with locally advanced NSCLC. A phase
I/II study of celecoxib and chemoradiation has also been initiat-
ed in patients with locally advanced cervical cancer. Early
phase studies are being carried out with selective COX-2
inhibitors in combination with radiation in patients with
esophageal cancer and glioblastoma multiforme (Choy and
Milas, 2003).
Selective COX-2 inhibitors may also act by COX-2-
independent mechanisms
Studies utilizing genetically engineered mice have firmly estab-
lished the link between COX-2 and carcinogenesis. Whether
pharmacological inhibitors of COX-2 suppress carcinogenesis
exclusively by inhibiting COX-2 is less certain. For example,
high concentrations of selective COX-2 inhibitors suppress the
growth of cells in culture that do not express COX-2 (Waskewich
et al., 2002). It is possible, therefore, that the anticancer activity
of selective COX-2 inhibitors may also reflect COX-2-indepen-
dent effects.
Conclusions and future directions
Significant progress has been made in defining the link between
COX-2 and carcinogenesis, but many important questions
remain unanswered. First, it will be important to establish
whether selective COX-2 inhibitors are effective in preventing or
treating cancer. Because numerous clinical trials are ongoing,
valuable information should be forthcoming in the not-too-dis-
tant future. Selective COX-2 inhibitors have been extensively
used to treat arthritis and pain for several years. Hence, epi-
demiological studies are anticipated that should provide addi-
tional insights about the relationship between use of selective
COX-2 inhibitors and the relative risk of developing a spectrum
of malignancies (Rahme et al., 2003).
Selective COX-2 inhibitors have an excellent safety profile
when given as monotherapy to arthritis patients. Ongoing place-
bo-controlled trials, including the colorectal adenoma preven-
tion trials, will provide additional useful safety data. In addition
to assessing efficacy, the safety of selective COX-2 inhibitors
needs to be carefully monitored in ongoing cancer treatment
studies. More experience is needed to know whether the excel-
lent safety profile established in arthritis patients translates to
cancer patients receiving chemotherapy or radiation.
Additional mechanistic studies are warranted.The impact of
cytotoxic therapy on levels of COX-2 in tumors should be more
fully defined. If selective COX-2 inhibitors are found to possess
significant antiangiogenic activity in clinical trials (Ferrandina et
al., 2003), these agents could be useful in the treatment of a
range of tumor types. Organ site-specific mechanisms should
be explored. For example, COX-2-derived-PGs stimulate aro-
matase activity and, thereby, estrogen biosynthesis. It will be
important to determine whether a selective COX-2 inhibitor sup-
presses aromatase activity in breast cancer. Possibly, the risk of
breast cancer will be reduced in postmenopausal women who
chronically use selective COX-2 inhibitors as a treatment for
arthritis. Given the apparent significance of COX-2 in carcino-
genesis, it will be worthwhile to investigate whether other forms
of targeted therapy suppress COX-2 levels. For example,
agents that target HER-2/neu or EGFR might suppress levels of
COX-2. Finally, more work should be done to investigate the
COX-2-independent effects of different selective COX-2
inhibitors. This could impact on both agent selection and possi-
bly dose optimization.
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